pyroglutamic acid Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: [Mg+2].OC1=N[C@@H](CC1)C(=O)[O-].OC2=N[C@@H](CC2)C(=O)[O-]
  • InChIKey: JQAACYUZYRBHGG-QHTZZOMLSA-L
  • Mol. Mass: 280.52
  • ALogP: -0.65
  • ChEMBL Molecules:
    magnesium pidolate  
    pidolic acid  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

(−)-2-pyrrolidone-5-carboxylic acid | glutimic acid | l-5-pyrrolidone-2-carboxylic acid | l-pyroglutamic acid | l-pyrrolidone carboxylic acid | magnesium pidolate | pca | pidolic acid | pidolic acid magnesium salt | pyroglutamic acid | (s)-(−)-2-pyrrolidone-5-carboxylic acid | (s)-pyroglutamic acid

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Dietary Supplements

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Anemia, Sickle Cell (Phase 1)

Diabetes Mellitus (Phase 4)

Healthy Volunteers (Phase 1)

Hemoglobin SC Disease (Phase 2)

Metabolic Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue